Norway · Delayed Price · Currency is NOK Aker BioMarine ASA Earnings Call Transcripts
Fiscal Year 2025
-
Q4 2025 saw 6% revenue and 66% EBITDA growth, led by a 28% surge in Human Health Ingredients, while consumer health declined 8%. Strategic focus is on maximizing Human Health Ingredients value, with strong guidance for 2026 and ongoing capacity expansion.
-
Q2 and Q3 2025 saw double-digit revenue and EBITDA growth, led by Human Health Ingredients and Consumer Health Products, with improved margins and operational leverage. The company is addressing production challenges, expanding in Asia, and expects continued growth, while managing risks from tariffs and restructuring.
-
Q2 2025 saw 12% revenue growth and 41% higher adjusted EBITDA, led by strong human health and consumer health segments. Operational leverage, cost reallocation, and product innovation drove margin gains, while a $15 million impairment was taken on the protein plant due to tariff uncertainty.
-
Q1 2025 saw 5% revenue growth and a 59% rise in adjusted EBITDA, led by strong human health segment performance and cost control. New clinical trials, retail partnerships, and market expansion underpin a positive outlook, with risks from tariffs and market timing mitigated.
Fiscal Year 2024
-
Q4 2024 saw 7% revenue growth and a near tripling of EBITDA, led by Human Health Ingredients, while Consumer Health Products declined but is expected to rebound in 2025. Restructuring and cost optimization are ongoing, with strong global demand and new product launches supporting future growth.
-
Q3 2024 saw the closure of the Feed Ingredients sale, a $214M net gain, and a $373M dividend. Human Health Ingredients and Emerging Business segments drove EBITDA growth, while cost optimization and refinancing strengthened the balance sheet.
-
Q2 saw the $590M sale of the Feed Ingredient business, with remaining operations focusing on human health and nutrition. Revenue grew 6% to $94M, EBITDA rose 35%, and an extraordinary dividend is planned post-transaction. Human Health Ingredient and international channels showed strong growth.